Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22316962 | 0.87 | ADRA2A (0.36) | ADRA2ACYP2D6ADRA2BADRA2CADRA1D | |
| SCHEMBL19755625 | 0.87 | HRH3 (0.36) | HRH3ADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL2741665 | 0.84 | KCNH2 (0.38) | HRH3KCNH2ALDH1A1LMNATSHR | |
| SCHEMBL19708316 | 0.83 | ADRA2A (0.33) | ADRA2ACYP2D6ADRA2BADRA2CADRA1D | |
| SCHEMBL16154960 | 0.81 | MAOA (0.53) | ADRA2ACYP2D6ADRA2BADRA2CADRA1D | |
| SCHEMBL19708231 | 0.81 | HRH3 (0.43) | HRH3ADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL23102140 | 0.80 | ADRA2A (0.57) | HRH3ADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL23509326 | 0.80 | CD44 (0.44) | HRH3ADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL24316260 | 0.80 | KCNH2 (0.48) | HRH3ADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL16154962 | 0.78 | PNMT (0.51) | HRH3DRD2DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | HRH3 3889/4885ADRA2A 4608/4885CYP2D6 4183/4885 |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | HRH3 1/4885ADRA2A 3119/4885CYP2D6 1673/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | HRH3 661/4885ADRA2A 1427/4885CYP2D6 829/4885 |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | HRH3 1/4885ADRA2A 3119/4885CYP2D6 1673/4885 |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | HRH3 4349/4885ADRA2A 4781/4885CYP2D6 2010/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | HRH3 661/4885ADRA2A 1427/4885CYP2D6 829/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | HRH3 1/4885ADRA2A 3119/4885CYP2D6 1673/4885 |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | HRH3 3984/4885ADRA2A 4789/4885CYP2D6 3315/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | HRH3 4349/4885ADRA2A 4781/4885CYP2D6 2010/4885 |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | HRH3 1247/4885ADRA2A 4108/4885CYP2D6 2451/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | HRH3 3889/4885ADRA2A 4608/4885CYP2D6 4183/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | HRH3 4349/4885ADRA2A 4781/4885CYP2D6 2010/4885 |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | HRH3 1247/4885ADRA2A 4108/4885CYP2D6 2451/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | HRH3 3497/4885ADRA2A 3282/4885CYP2D6 3473/4885 |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | HRH3 661/4885ADRA2A 1427/4885CYP2D6 829/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | HRH3 3809/4885ADRA2A 4785/4885CYP2D6 3145/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | HRH3 3375/4885ADRA2A 4319/4885CYP2D6 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.